Nexavar News and Research

RSS
Study reveals promising results for primary liver cancer patients treated with SIR-Spheres Y-90 resin microspheres

Study reveals promising results for primary liver cancer patients treated with SIR-Spheres Y-90 resin microspheres

MUSC Hollings Cancer Center receives $8.9 million grant to explore signaling in sphingolipids

MUSC Hollings Cancer Center receives $8.9 million grant to explore signaling in sphingolipids

Bayer-new phase 3 liver cancer data

Bayer-new phase 3 liver cancer data

SillaJen reports initiation of multinational randomized Phase 3 study of Pexa-Vec in HCC patients

SillaJen reports initiation of multinational randomized Phase 3 study of Pexa-Vec in HCC patients

China leads in pharma sector patent filings among BRIC Nations

China leads in pharma sector patent filings among BRIC Nations

Can-Fite's CF102 granted Orphan Drug Designation by EMA for treatment of hepatocellular carcinoma

Can-Fite's CF102 granted Orphan Drug Designation by EMA for treatment of hepatocellular carcinoma

VG Life Sciences receives U.S. patent for combination cancer therapy

VG Life Sciences receives U.S. patent for combination cancer therapy

Protein-signaling process accelerates work of gene mutation linked to common form of adult leukemia

Protein-signaling process accelerates work of gene mutation linked to common form of adult leukemia

Can-Fite receives EMA clearance to begin CF102 Phase II trial for treatment of HCC patients in Europe

Can-Fite receives EMA clearance to begin CF102 Phase II trial for treatment of HCC patients in Europe

Can-Fite seeks EMA Orphan Drug Designation for CF102 in HCC

Can-Fite seeks EMA Orphan Drug Designation for CF102 in HCC

SARAH study completes patient enrolment to evaluate treatment for primary liver cancer

SARAH study completes patient enrolment to evaluate treatment for primary liver cancer

Study results report no benefit from use of sunitinib, sorafenib among patients with kidney cancer

Study results report no benefit from use of sunitinib, sorafenib among patients with kidney cancer

Can-Fite BioPharma begins dosing in CF102 Phase II liver cancer trial

Can-Fite BioPharma begins dosing in CF102 Phase II liver cancer trial

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Can-Fite's CF102 drug gets approval in Israel for patient with hepatocellular carcinoma

Can-Fite's CF102 drug gets approval in Israel for patient with hepatocellular carcinoma

Bayer announces Health Canada approval of Nexavar for differentiated thyroid cancer treatment

Bayer announces Health Canada approval of Nexavar for differentiated thyroid cancer treatment

FDA approves Can-Fite's study protocol for CF102 Phase II clinical trial for advanced liver cancer

FDA approves Can-Fite's study protocol for CF102 Phase II clinical trial for advanced liver cancer

Bayer and Onyx announce Phase 3 trial evaluating use of NEXAVAR for patients with HCC after local ablation

Bayer and Onyx announce Phase 3 trial evaluating use of NEXAVAR for patients with HCC after local ablation

Combination treatments for unresectable and metastatic melanomas: an interview with Dr. Kiran Patel, Vice President & Medicines Development Leader for Oncology, GSK

Combination treatments for unresectable and metastatic melanomas: an interview with Dr. Kiran Patel, Vice President & Medicines Development Leader for Oncology, GSK

VG Life Sciences provides update to HCQ-sorafenib combination Phase I Study for advanced stage solid tumors

VG Life Sciences provides update to HCQ-sorafenib combination Phase I Study for advanced stage solid tumors